Last reviewed · How we verify

NCT00359645

Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population

Completed Phase 3 Last updated 16 May 2017
What this trial tests

Phase 3 trial testing Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years in Pharynx Cancer in 1,993 participants. Completed in 18 December 2015.

Timeline
21 June 2006
Primary endpoint
18 December 2015
18 December 2015

Quick facts

Lead sponsorGustave Roussy, Cancer Campus, Grand Paris
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment1,993
Start date21 June 2006
Primary completion18 December 2015
Estimated completion18 December 2015
Sites35 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris — full company profile →

Who can join

40 and older, any sex, with Pharynx Cancer or Larynx Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized multicenter trial to assess the impact of a screening program for heavy alcohol drinkers and smokers treated in alcohol addiction clinics on upper aerodigestive tract cancer mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pharynx Cancer

Currently open trials in the same condition.

Other Gustave Roussy, Cancer Campus, Grand Paris trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00359645.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing